Press Releases Corbus Pharmaceuticals Holdings, Inc.

Equities

CRBP

US21833P3010

Real-time Estimate Cboe BZX Other stock markets 09:56:03 2024-06-26 EDT			5-day change	1st Jan Change
43.78 ^USD	-1.29%		+4.41%	+637.58%

02:01pm	B. Riley Initiates Coverage on Corbus Pharmaceuticals With Buy Rating, $85 Price Target	MT
06-24	Corbus Pharmaceuticals Holdings, Inc.(NasdaqCM:CRBP) added to S&P Biotechnology Select Industry Index	CI

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstrate Encouraging Safety and Efficacy Observed in Patients with Nectin-4 Positive Tumors in a Clinical Update Presented at ASCO 2024	06-01	AQ
Corbus Pharmaceuticals to Present at the 45th Annual Goldman Sachs Global Healthcare Conference	05-30	AQ
Updated Phase 1 Clinical Data for SYS-6002 (CRB-701) to be presented at 2024 ASCO Annual Meeting	05-23	AQ
Corbus Pharmaceuticals to Participate in the 2024 RBC Capital Markets Global Healthcare Conference	05-09	AQ
Corbus Pharmaceuticals: Q1 Earnings Snapshot	05-07	AQ
Corbus Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update	05-07	AQ
Corbus Pharmaceuticals to Participate in the BTIG Obesity Health Forum	05-01	AQ
Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO Annual Meeting	04-24	AQ
Corbus Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC	04-02	AQ
Corbus Pharmaceuticals: Q4 Earnings Snapshot	03-12	AQ
Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update	03-12	AQ
Corbus Pharmaceuticals to Participate in the BMO Capital Markets Inaugural Obesity Summit	03-06	AQ
Corbus Pharmaceuticals Appoints Dr. Dominic Smethurst as Chief Medical Officer	02-28	AQ
Corbus Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference	02-06	AQ
Corbus Pharmaceuticals Announces Closing of $94.5 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares	02-02	AQ
Corbus Pharmaceuticals Announces Pricing of Public Offering	01-31	AQ
Corbus Pharmaceuticals Announces Proposed Public Offering	01-30	AQ
Investors Take Note as Corbus Pharma Releases Data for ADC Tumor Candidate	01-29	AQ
CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting Antibody Drug Conjugate Demonstrates Encouraging Safety and Efficacy in Patients with Nectin-4 Positive Tumors in First-In-Human Study Presented at ASCO-GU 2024	01-26	AQ
Corbus Pharmaceuticals - Phase 1 Clinical Data for SYS6002 to be presented at 2024 ASCO GU	01-24	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Corbus Pharmaceuticals Holdings, Inc.

Equities

CRBP

US21833P3010

Press Releases

Filters